GGrantIndex
Sort

64,565 grants matching drug discovery

Small molecule mitochondria-targeted therapeutics for AD

$785,056
Eugenia Trushina · Mayo Clinic Rochester · UG3 · FY2021 · NS

Entry and replication of positive-sense, RNA viruses

$785,051
Joseph Marcotrigiano · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI

Making the HIV-1 gp41 pocket amenable to small-molecule drug discovery

$785,000
Peter S Kim · Stanford University · DP1 · FY2019 · DA

Making the HIV-1 gp41 pocket amenable to small-molecule drug discovery

$785,000
Peter S Kim · Stanford University · DP1 · FY2017 · DA

Making the HIV-1 gp41 pocket amenable to small-molecule drug discovery

$785,000
Peter S Kim · Stanford University · DP1 · FY2021 · DA

Making the HIV-1 gp41 pocket amenable to small-molecule drug discovery

$785,000
Peter S Kim · Stanford University · DP1 · FY2018 · DA

Making the HIV-1 gp41 pocket amenable to small-molecule drug discovery

$785,000
Peter S Kim · Stanford University · DP1 · FY2020 · DA

Synthetic Biology Platforms for Natural Product Discovery and Biosynthesis

$785,000
Christina D Smolke · Stanford University · DP1 · FY2014 · AT

Synthetic Biology Platforms for Natural Product Discovery and Biosynthesis

$785,000
Christina D Smolke · Stanford University · DP1 · FY2016 · AT

Synthetic Biology Platforms for Natural Product Discovery and Biosynthesis

$785,000
Christina D Smolke · Stanford University · DP1 · FY2015 · AT

Synthetic Biology Platforms for Natural Product Discovery and Biosynthesis

$785,000
Christina D Smolke · Stanford University · DP1 · FY2012 · AT

Development of GCPII inhibitors for the treatment of age-related cognitive disorders

$784,969
Takashi Tsukamoto · Johns Hopkins University · R01 · FY2024 · AG

Clinical and Translational Science Award

$784,809
Robert Stanley Sherwin · Yale University · KL2 · FY2009 · RR

Drug Discovery for Human African Trypanosomiasis

$784,716
Michael H Gelb · University Of Washington · R01 · FY2017 · AI

Investigating nanobodies to target multidrug resistant bacterial pathogens

$784,687
Bryan William Davies · University Of Texas At Austin · R01 · FY2020 · AI

Nicotinic Ligands for Smoking Cessation

$784,670
Henry A. Lester · California Institute Of Technology · U19 · FY2011 · DA

Development of GCPII inhibitors for the treatment of age-related cognitive disorders

$784,616
Takashi Tsukamoto · Johns Hopkins University · R01 · FY2023 · AG

Mechanisms of Prion Protein Toxicity

$784,573
David A Harris · Boston University Medical Campus · R01 · FY2022 · NS

Drug Development for Prostate Cancer and other Metastatic Processes

$784,504
William Douglas Figg · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA

Engineering biophysical microtechnologies for hematologic applications in health and disease

$784,500
Wilbur A Lam · Emory University · R35 · FY2023 · HL

Structural Studies of Opioid Receptors, p 55

$784,494
Vadim Cherezov · University Of Southern California · P01 · FY2016 · DA

Development of a Mirror-Image Natural Product as an Antiarrhythmic Therapeutic

$784,438
Jeffrey Nicholas Johnston · Vanderbilt University · R01 · FY2021 · HL

Project 2: Development of Small Molecule Inhibitors of IL-17A Pathway for Treatment of Severe Asthma

$784,421
Serpil C. Erzurum · Cleveland Clinic Lerner Com-Cwru · P01 · FY2020 · HL

Project 2: Development of Small Molecule Inhibitors of IL-17A Pathway for Treatment of Severe Asthma

$784,421
Xiaoxia Li · Cleveland Clinic Lerner Com-Cwru · P01 · FY2019 · HL

Uncovering novel biological processes and pathogenic mechanisms for glaucoma

$784,373
Ayellet Vered Segre · Massachusetts Eye And Ear Infirmary · R01 · FY2020 · EY